Loureirin A is a narrow-spectrum antimicrobial agent against <i>Helicobacter pylori</i>.

ABSTRACT: Currently, Helicobacter pylori eradication by antibiotic therapy faces various challenges, including antibiotic resistance, side effects on intestinal commensal bacteria, and patient compliance. In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro. LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori. The combination of LrA and omeprazole showed promising anti-H. pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models

SUBMITTER: Tong Q 

PROVIDER: S-EPMC11620498 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature